The prognostic value of CD30

The definitive role of prevalence and intensity of CD30 in prognosis is evolving. Where defined, the prognostic value of CD30 expression is variable and lymphoma subtype–specific.

In one study of peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS), expression of CD30 in ≥80% of cells was associated with an extremely poor prognosis: 5-year overall survival (OS) of only 19% compared to 32% in PTCL-NOS when immunophenotype was not considered.1 In contrast, another study reported that OS of patients with CD30-positive PTCL-NOS is superior to that of patients with CD30-negative PTCL-NOS; however, not all studies use the same cutoffs for CD30 positivity.2 These conflicting results illustrate the need for larger studies in a controlled setting.

High prevalence of CD30-positive cells has a variable association with prognosis in PTCL–NOS1,2

Study N CD30 cutoff CD30-positive prognosis Statistically significant
Savage et al1331 ≥80% of cells CD30-positivePoor N/A
Bisig et al2 36 >75% of cells CD30-positive Superior Not significant

In diffuse large B-cell lymphoma (DLBCL), CD30 expression is a favorable prognostic factor based on a large, multicenter study. Patients with >20% CD30-positive cells had a 5-year OS of 79% vs 59% in patients with <20% CD30-positive cells. This trend was maintained in both the germinal center B-cell (GCB) and activated B-cell (ABC) subtypes, suggesting CD30 expression defines a unique subgroup of DLBCL with more favorable clinical outcomes.3

Prognostic impact of CD30 expression in DLBCL3

Prognostic impact of CD30 expression in DLBCL

For more information on CD30 in prognosis, click here.


  1. Savage KJ, Harris NL, Vose JM, et al; for International Peripheral T-Cell Lymphoma Project. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood. 2008;111(12):5496-5504.
  2. Bisig B, de Reyniès A, Bonnet C, et al. CD30-positive peripheral T-cell lymphomas share molecular and phenotypic features. Haematologica. 2013;98(8):1250-1258.
  3. Hu S, Xu-Monette ZY, Balasubramanyam A, et al. CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program study. Blood. 2013;121(14):2715-2724.


NCCN recommends CD30-thumb

NCCN recommends CD30

The NCCN Guidelines* recommend CD30 testing for the differential diagnosis of Hodgkin and certain non-Hodgkin lymphomas...

Clinical relevance of CD30-thumb

The clinical relevance of CD30

Appropriate management of patients with lymphoma depends on an accurate diagnosis...

CD30 in NHL prognosis-thumb

CD30 in NHL prognosis

The definitive role of prevalence and intensity of CD30 in prognosis is evolving...


Study finds CD30 in 17 cancers

In a study of over 1,500 patients with nonlymphomatous malignancies, 17 different diagnoses were associated...


CD30 in Burkitt lymphoma

25% of Burkitt lymphoma cases express CD30. The endemic variant, African Burkitt lymphoma...

ptcl OS-thumb

CD30 and overall survival in PTCL‑NOS

A recent study found that CD30 expression is an adverse predictor of survival in peripheral T-cell lymphoma...

germ vells thumb

CD30 screening in germ cell tumors

CD30 is strongly expressed in more than 95% of embryonal carcinomas, while other germ cell tumors lack CD30...

methods thumb

Methods of detecting CD30

CD30 expression can be analyzed using immunohistochemistry on fixed tissue or flow cytometry on live cells...

*Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non-Hodgkin’s Lymphomas V.2.2013 and Hodgkin Lymphoma V.2.2013. © National Comprehensive Cancer Network, Inc 2013. All rights reserved. Accessed September 24, 2013. To view the most recent and complete version of the guideline, go online to NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, NCCN GUIDELINES®, and all other NCCN Content are trademarks owned by the National Comprehensive Cancer Network, Inc.